Travere Therapeutics to Present at Kidney Foundation Meetings and ERA Congress

Travere Therapeutics, Inc. has announced the presentation of nine abstracts related to rare kidney diseases at upcoming medical conferences. These include the National Kidney Foundation (NKF) Spring Clinical Meetings in Long Beach, California, from May 14-18, 2024, and the European Renal Association (ERA) Congress in Stockholm, from May 23-26, 2024.

The presentations will focus on data supporting the use of FILSPARI® (sparsentan) as a foundational therapy for IgA nephropathy (IgAN), a condition characterized by the accumulation of immunoglobulin A in the kidneys, leading to progressive kidney damage. FILSPARI has shown promise in slowing kidney function decline compared to traditional renin-angiotensin system inhibitors (RASi).

At the NKF meeting, Travere will present comparative analyses from the Phase 3 PROTECT Study, which highlights FILSPARI's efficacy in slowing kidney function decline versus RAS inhibition in both real-world use and clinical trials for IgAN patients. Additionally, new findings from the 48-week SPARTAN Study will be presented, showcasing FILSPARI as a first-line treatment for newly diagnosed IgAN patients. These findings have earned recognition as a top-rated abstract by the NKF.

During the ERA Congress, the company will present a matching-adjusted indirect comparison of the two-year efficacy outcomes between FILSPARI from the PROTECT Study and targeted-release formulation budesonide plus RAS inhibition from the NefIgArd trial. The goal is to demonstrate FILSPARI’s superior efficacy over the established standard of care.

Dr. Jula Inrig, the Chief Medical Officer of Travere Therapeutics, emphasized the importance of these findings, stating that "a non-immunosuppressive therapy that targets injury directly in the kidney can reshape optimal foundational patient care in IgAN."

Specific sessions at the NKF meeting will include:
- An oral presentation comparing eGFR slopes in the PROTECT Study with the UK RaDaR IgA Nephropathy population and the control arm of the NefIgArd trial.
- Poster presentations on the clinically meaningful treatment effects of sparsentan compared to irbesartan in IgAN patients from the PROTECT trial.
- Preliminary findings from the SPARTAN trial on sparsentan as a first-line treatment for incident IgAN patients.
- Results from the DUPLEX trial comparing sparsentan to irbesartan in patients with Focal Segmental Glomerulosclerosis (FSGS).

At the ERA Congress, the following topics will be covered:
- Oral presentations on proteinuria and eGFR outcomes from the PROTECT and NefIgArd studies.
- Comparisons of eGFR slopes in the PROTECT Study with the UK RaDaR population and the control arm of the NefIgArd trial.
- An analysis of the natural history of idiopathic nephrotic syndrome using data from the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort.
- Direct effects of sparsentan on the glomerular capillary wall in nephrotic syndrome.

Additionally, a poster at the ERA Congress will discuss the humanistic burden of IgAN and FSGS on patients and caregivers in Europe.

IgA nephropathy, also known as Berger's disease, is a progressive kidney disorder where IgA deposits damage the kidneys' filtering mechanisms, leading to symptoms such as blood and protein in the urine, swelling, and high blood pressure. It is a leading cause of kidney failure globally, affecting up to 150,000 people in the U.S. alone. Focal Segmental Glomerulosclerosis (FSGS) is another rare kidney disorder marked by scarring and proteinuria, often leading to kidney failure.

Travere Therapeutics is committed to improving the lives of patients with rare diseases by developing and delivering life-changing therapies. FILSPARI is currently indicated in the U.S. to reduce proteinuria in adults with IgAN at risk of rapid disease progression. However, its ability to slow kidney function decline has yet to be established, and continued approval depends on further verification of clinical benefits in confirmatory trials.

In summary, Travere Therapeutics is set to present compelling data supporting FILSPARI’s potential to become a cornerstone treatment in managing IgAN.